20s Proteasome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

20s Proteasome Pipeline Drugs Market Report Overview

The 20s Proteasome pipeline drugs market research report outlays comprehensive information on the 20s Proteasome targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in 20s Proteasome targeted therapeutics development with respective active and dormant or discontinued projects.

20s Proteasome Pipeline Drugs Market Segmentation by Therapy Areas

The key therapy areas in the 20s Proteasome pipeline drugs market are oncology, immunology, infectious disease, and metabolic disorders.

20s Proteasome Pipeline Drugs Market Analysis, by Therapy Areas

20s Proteasome Pipeline Drugs Market Analysis, by Therapy Areas

For more 20s Proteasome pipeline drugs therapy area insights, download a free report sample

20s Proteasome Pipeline Drugs Market Segmentation by Mechanism of Actions

The key mechanism of action in the 20s Proteasome pipeline drugs market is 20s Proteasome Inhibitor.

20s Proteasome Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the 20s Proteasome pipeline drugs market are intravenous, oral, and transdermal.

20s Proteasome Pipeline Drugs Market Analysis, by Routes of Administration

20s Proteasome Pipeline Drugs Market Analysis, by Routes of Administration

For more 20s Proteasome pipeline drugs routes of administration insights, download a free report sample

20s Proteasome Pipeline Drugs Market Segmentation by Molecule Types

The key molecule type in the 20s Proteasome pipeline drugs market is small molecule.

Competitive Landscape

The leading companies in the 20s Proteasome pipeline drugs market are Amgen Inc, Bristol-Myers Squibb Co, Centrax International Inc, HuniLife Biotechnology Inc, Jiangsu Chai Tai Fenghai Pharmaceutical Co Ltd, and Zymergen Inc.

20s Proteasome Pipeline Drugs Market Analysis, by Companies

20s Proteasome Pipeline Drugs Market Analysis, by Companies

To know more about the 20s Proteasome pipeline drugs companies, download a free report sample

20s Proteasome Pipeline Drugs Market Report Overview

Key Therapy Areas Oncology, Immunology, Infectious Disease, and Metabolic Disorders
Key Mechanism of Actions 20s Proteasome Inhibitor
Key Routes of Administration Intravenous, Oral, and Transdermal
Key Molecule Types Small Molecule
Leading Companies Amgen Inc, Bristol-Myers Squibb Co, Centrax International Inc, HuniLife Biotechnology Inc, Jiangsu Chai Tai Fenghai Pharmaceutical Co Ltd, and Zymergen Inc

Scope

This report provides:

  • A snapshot of the global therapeutic landscape for 20s Proteasome.
  • Reviews of 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which includes product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects.
  • Assessment of 20s Proteasome targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
  • Summaries of all the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to 20s Proteasome targeted therapeutics.

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for 20s Proteasome. Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding 20s Proteasome development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Amgen Inc
Bristol-Myers Squibb Co
Centrax International Inc
HuniLife Biotechnology Inc
Jiangsu Chai Tai Fenghai Pharmaceutical Co Ltd
Zymergen Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

20s Proteasome – Overview

20s Proteasome – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

20s Proteasome – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

20s Proteasome – Companies Involved in Therapeutics Development

Amgen Inc

Bristol-Myers Squibb Co

Centrax International Inc

HuniLife Biotechnology Inc

Jiangsu Chai Tai Fenghai Pharmaceutical Co Ltd

Zymergen Inc

20s Proteasome – Drug Profiles

carfilzomib – Drug Profile

Product Description

Mechanism Of Action

History of Events

CX-13608 – Drug Profile

Product Description

Mechanism Of Action

HuL-002 – Drug Profile

Product Description

Mechanism Of Action

History of Events

marizomib – Drug Profile

Product Description

Mechanism Of Action

History of Events

NNU-546 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Ridaifen – Drug Profile

Product Description

Mechanism Of Action

History of Events

RTSV-5 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit 20S Proteasome for Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit 20s Proteasome for Tuberculosis – Drug Profile

Product Description

Mechanism Of Action

History of Events

TIR-199 – Drug Profile

Product Description

Mechanism Of Action

History of Events

20s Proteasome – Dormant Products

20s Proteasome – Product Development Milestones

Featured News & Press Releases

Dec 06, 2021: Amgen announces new data on Nplate to be presented at ASH 2021

Dec 06, 2021: Amgen announces new data on KYPROLIS to be presented at ASH 2021

Jul 09, 2021: BeiGene announces the approval in China of KYPROLIS (Carfilzomib) for injection for adult patients with relapsed or refractory multiple myeloma

Mar 22, 2021: Triple therapy recommended by NICE for patients with multiple myeloma

Nov 30, 2020: Amgen announces new data on KYPROLIS At ASH 2020

Nov 12, 2020: CHMP adopts a positive opinion recommending a change to the terms of the marketing authorisation for Kyprolis

Aug 20, 2020: FDA approves new KYPROLIS (carfilzomib) combination regimen with DARZALEX (daratumumab) and Dexamethasone in both once- and twice-weekly dosing regimens

May 14, 2020: Oncolytics Biotech announces publication of abstract on Kyprolis at the 2020 American Society of Clinical Oncology Virtual Annual Meeting

May 13, 2020: Amgen presents update on KYPROLIS at ASCO 2020

May 05, 2020: KYPROLIS (carfilzomib) patents upheld against generic manufacturer

Dec 11, 2019: Amgen reports positive data in multiple myeloma study

Dec 02, 2019: Amgen announces data to be presented on KYPROLIS (carfilzomib) at ASH 2019

Sep 13, 2019: Amgen announces phase 3 CANDOR study combining KYPROLIS (carfilzomib) and DARZALEX (daratumumab) meets primary endpoint of progression-free survival

Sep 12, 2019: Amgen highlights new data From KYPROLIS (carfilzomib) and Oncology Pipeline At IMW 2019

Aug 19, 2019: Carfilzomib (Kyprolis): reminder of risk of potentially fatal cardiac events

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Amgen Inc, 2022

Pipeline by Bristol-Myers Squibb Co, 2022

Pipeline by Centrax International Inc, 2022

Pipeline by HuniLife Biotechnology Inc, 2022

Pipeline by Jiangsu Chai Tai Fenghai Pharmaceutical Co Ltd, 2022

Pipeline by Zymergen Inc, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Frequently asked questions

20s Proteasome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

20s Proteasome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at 20s Proteasome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live 20s Proteasome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.